Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:ADD NYSE:AGE NYSE:MCS NASDAQ:PSM NYSE:SB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADDArctic Star ExplorationC$0.01-33.3%C$0.01C$0.01▼C$0.03C$2.23M1.56298,295 shs1.30 million shsAGEAgeX Therapeutics$4.54$11.07▼$35.71$11.99M1.183,849 shs3,700 shsMCSMarcus$13.09-2.5%$15.16$12.95▼$23.16$420.20M1.02219,476 shs295,371 shsPSMPrincipal U.S. Small-MidCap Multi-Factor ETF$29.53$29.53$15.33▼$29.53$11.81MN/A921 shsN/ASBSafe Bulkers$4.31+0.2%$4.39$3.02▼$4.72$439.98M1.28371,931 shs280,796 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADDArctic Star Exploration0.00%0.00%0.00%0.00%0.00%AGEAgeX Therapeutics0.00%0.00%0.00%0.00%0.00%MCSMarcus-2.32%-5.42%-18.09%-26.50%-18.09%PSMPrincipal U.S. Small-MidCap Multi-Factor ETF0.00%0.00%0.00%0.00%0.00%SBSafe Bulkers+0.12%-0.35%-5.69%+4.36%-2.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADDArctic Star ExplorationC$0.01-33.3%C$0.01C$0.01▼C$0.03C$2.23M1.56298,295 shs1.30 million shsAGEAgeX Therapeutics$4.54$11.07▼$35.71$11.99M1.183,849 shs3,700 shsMCSMarcus$13.09-2.5%$15.16$12.95▼$23.16$420.20M1.02219,476 shs295,371 shsPSMPrincipal U.S. Small-MidCap Multi-Factor ETF$29.53$29.53$15.33▼$29.53$11.81MN/A921 shsN/ASBSafe Bulkers$4.31+0.2%$4.39$3.02▼$4.72$439.98M1.28371,931 shs280,796 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADDArctic Star Exploration0.00%0.00%0.00%0.00%0.00%AGEAgeX Therapeutics0.00%0.00%0.00%0.00%0.00%MCSMarcus-2.32%-5.42%-18.09%-26.50%-18.09%PSMPrincipal U.S. Small-MidCap Multi-Factor ETF0.00%0.00%0.00%0.00%0.00%SBSafe Bulkers+0.12%-0.35%-5.69%+4.36%-2.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADDArctic Star Exploration 0.00N/AN/AN/AAGEAgeX Therapeutics 0.00N/AN/AN/AMCSMarcus 2.83Moderate Buy$23.7581.44% UpsidePSMPrincipal U.S. Small-MidCap Multi-Factor ETF 0.00N/AN/AN/ASBSafe Bulkers 2.50Moderate Buy$4.473.63% UpsideCurrent Analyst Ratings BreakdownLatest SB, ADD, MCS, AGE, and PSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025MCSMarcusWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025SBSafe BulkersWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/6/2025MCSMarcusBenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$25.00 ➝ $22.009/29/2025SBSafe BulkersZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/27/2025MCSMarcusWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025SBSafe BulkersWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/23/2025MCSMarcusBarrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$25.009/18/2025MCSMarcusZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/4/2025MCSMarcusBarrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$25.007/18/2025MCSMarcusWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$24.007/18/2025MCSMarcusWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$24.00(Data available from 10/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADDArctic Star ExplorationN/AN/AC$0.00 per share12.50C$0.04 per shareN/AAGEAgeX Therapeutics$140K0.00N/AN/A($16.07) per share0.00MCSMarcus$735.56M0.56$2.40 per share5.45$14.70 per share0.89PSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/AN/AN/AN/AN/AN/ASBSafe Bulkers$307.63M1.43$1.34 per share3.22$7.79 per share0.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADDArctic Star Exploration-C$1.03MN/AN/A∞N/AN/A-9.59%-5.24%N/AAGEAgeX Therapeutics-$14.80M-$13.03N/AN/AN/A-10,424.65%N/A-120.90%N/AMCSMarcus-$7.79M$0.4529.0928.462.461.91%4.28%1.88%10/30/2025 (Estimated)PSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/AN/A0.00∞N/AN/AN/AN/AN/ASBSafe Bulkers$97.38M$0.4310.027.43N/A19.25%5.80%3.45%11/12/2025 (Estimated)Latest SB, ADD, MCS, AGE, and PSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025SBSafe Bulkers$0.10N/AN/AN/A$66.64 millionN/A10/30/2025Q3 2025MCSMarcus$0.48N/AN/AN/A$214.14 millionN/A8/1/2025Q2 2025MCSMarcus$0.19$0.23+$0.04$0.23$192.79 million$206.04 million7/29/2025Q2 2025SBSafe Bulkers$0.08$0.01-$0.07$0.02$60.40 million$65.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADDArctic Star ExplorationN/A9.88%N/AN/AN/AAGEAgeX TherapeuticsN/AN/AN/AN/AN/AMCSMarcus$0.322.44%N/A71.11%2 YearsPSMPrincipal U.S. Small-MidCap Multi-Factor ETF$0.431.46%N/AN/AN/ASBSafe Bulkers$0.204.64%N/A46.51%N/ALatest SB, ADD, MCS, AGE, and PSM DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/5/2025MCSMarcusquarterly$0.082.15%8/25/20258/25/20259/15/20257/29/2025SBSafe Bulkersquarterly$0.055.2%8/21/20258/21/20259/5/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADDArctic Star Exploration4.520.323.10AGEAgeX TherapeuticsN/A0.130.36MCSMarcus0.400.390.39PSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/AN/AN/ASBSafe Bulkers0.601.701.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADDArctic Star ExplorationN/AAGEAgeX Therapeutics12.50%MCSMarcus81.57%PSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/ASBSafe Bulkers21.69%Insider OwnershipCompanyInsider OwnershipADDArctic Star Exploration2.22%AGEAgeX Therapeutics6.50%MCSMarcus5.00%PSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/ASBSafe Bulkers40.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADDArctic Star Exploration50223.07 millionN/ANot OptionableAGEAgeX Therapeutics51.08 million1.01 millionNot OptionableMCSMarcus8,55031.31 million29.75 millionOptionablePSMPrincipal U.S. Small-MidCap Multi-Factor ETFN/A400,000N/ANot OptionableSBSafe Bulkers920102.32 million61.14 millionOptionableSB, ADD, MCS, AGE, and PSM HeadlinesRecent News About These CompaniesSafe Bulkers (NYSE:SB) Stock Passes Above 200-Day Moving Average - Should You Sell?4 hours ago | marketbeat.comSafe Bulkers Stays Afloat Amid The Stormy Market EnvironmentOctober 15 at 7:01 AM | seekingalpha.comSafe Bulkers (NYSE:SB) Shares Pass Above Two Hundred Day Moving Average - Time to Sell?October 10, 2025 | marketbeat.comSafe Bulkers' (SB) Hold (C) Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | marketbeat.comSafe Bulkers, Inc. to Participate in Capital Link’s 17th Annual New York Maritime Forum on October 14, 2025October 7, 2025 | finance.yahoo.comSafe Bulkers, Inc. to Participate in Capital Link's 17th Annual New York Maritime Forum on October 14, 2025October 7, 2025 | globenewswire.comThose who invested in Safe Bulkers (NYSE:SB) five years ago are up 401%October 6, 2025 | finance.yahoo.comSafe Bulkers Declares Quarterly Dividends on Preferred SharesOctober 3, 2025 | tipranks.comSafe Bulkers, Inc. Declares Quarterly Dividend on its 8.00% Series C Cumulative Redeemable Perpetual Preferred Shares; 8.00% Series D Cumulative Redeemable Perpetual Preferred SharesOctober 3, 2025 | globenewswire.comSafe Bulkers (NYSE:SB) Upgraded at Zacks ResearchOctober 1, 2025 | marketbeat.comSafe Bulkers (NYSE:SB) Shares Pass Above 200-Day Moving Average - Here's WhySeptember 24, 2025 | marketbeat.comSafe Bulkers: A Calmer Ship Sailing At A DiscountSeptember 24, 2025 | seekingalpha.comGoldman Sachs Group Inc. Acquires 91,662 Shares of Safe Bulkers, Inc $SBSeptember 17, 2025 | marketbeat.comSafe Bulkers, Inc. Announces Results of 2025 Annual Meeting of StockholdersSeptember 16, 2025 | globenewswire.comSafe Bulkers (SB) Q2 Revenue Beats Estimates, EPS DisappointsAugust 13, 2025 | insidermonkey.comSafe Bulkers Sells Kamsarmax Vessel as Part of Fleet Renewal StrategyAugust 13, 2025 | msn.comSafe Bulkers completes sale of oldest Kamsarmax vesselsAugust 13, 2025 | msn.comSafe Bulkers enters agreement for sale of MV Pedhoulas MerchantAugust 12, 2025 | msn.comSafe Bulkers, Inc. Announces Sale of a 2006-Built Kamsarmax Class Dry-bulk Vessel | SB Stock NewsAugust 12, 2025 | gurufocus.comSafe Bulkers, Inc. Announces Sale of MV Pedhoulas Merchant for $11.5 Million as Part of Fleet Renewal StrategyAugust 12, 2025 | quiverquant.comQSafe Bulkers, Inc. Announces Sale of a 2006-Built Kamsarmax Class Dry-bulk VesselAugust 12, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhy Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025After the Fed's Rate Cut, PNC Could See a Mortgage Refinance BoomBy Jordan Chussler | September 21, 2025Can Advantage2 Help Overcome D-Wave's Share Price Plateau?By Nathan Reiff | September 18, 2025CrowdStrike Stock Set for Breakout as Agentic AI Demand SurgesBy Chris Markoch | September 17, 2025Is BigBear.ai the Next Palantir? By Gabriel Osorio-Mazilli | October 3, 2025SB, ADD, MCS, AGE, and PSM Company DescriptionsArctic Star Exploration CVE:ADDC$0.01 -0.01 (-33.33%) As of 07/4/2025Arctic Star Exploration Corp., a junior natural resource company, acquires, explores, and develops mineral properties in Canada and Finland. It primarily explores for diamond. The company's flagship project is the Diagras diamond project located in the north-eastern part of the prolific Lac de Gras kimberlite field. The company was formerly known as Arctic Star Diamond Corp. and changed its name to Arctic Star Exploration Corp. in July 2011. Arctic Star Exploration Corp. was incorporated in 2001 and is headquartered in Vancouver, Canada.AgeX Therapeutics NYSE:AGEAgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.Marcus NYSE:MCS$13.09 -0.33 (-2.46%) Closing price 10/16/2025 03:59 PM EasternExtended Trading$13.08 0.00 (-0.04%) As of 04:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Marcus Corporation, together with its subsidiaries, owns and operates movie theatres, and hotels and resorts in the United States. It operates a family entertainment center and multiscreen motion picture theatres under the Big Screen Bistro, Big Screen Bistro Express, BistroPlex, and Movie Tavern by Marcus brand names. The company also owns and operates full-service hotels and resorts, as well as manages full-service hotels, resorts, and other properties. In addition, it provides hospitality management services, including check-in, housekeeping, and maintenance for a vacation ownership development; and manages condominium hotels under long-term management contracts. The Marcus Corporation was founded in 1935 and is headquartered in Milwaukee, Wisconsin.Principal U.S. Small-MidCap Multi-Factor ETF NASDAQ:PSMSafe Bulkers NYSE:SB$4.31 +0.01 (+0.23%) Closing price 10/16/2025 03:59 PM EasternExtended Trading$4.29 -0.02 (-0.46%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Safe Bulkers, Inc., together with its subsidiaries, provides marine drybulk transportation services. It owns and operates drybulk vessels for transporting bulk cargoes primarily coal, grain, and iron ore. The company has a fleet of 47 drybulk vessels having an aggregate carrying capacity of 4,719,600 deadweight tons. Its fleet consists of 10 Panamax class vessels, 11 Kamsarmax class vessels, 18 post-Panamax class vessels, and 8 Capesize class vessels. Safe Bulkers, Inc. was incorporated in 2007 and is based in Monaco. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Buys Rival's Patent Treasure Trove in Strategic Move Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.